Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.12

-1.4%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$929.55M
EPS-3.7200
P/E Ratio-4.07
Earnings Date08/06/2026

cgem

Operating Cash Flow

Last Annual Value

-175.75M

3-Year CAGR

-12%

5-Year CAGR

-43%

10-Year CAGR

-29%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Operating Cash Flow

CGEM · NASDAQ
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
-175.75M
N/AN/AN/A 
41.70M
-27.3%-14.7%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
-40.81M
N/AN/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
70.70M
13.5%-10.5%N/A
-74.35M
N/AN/AN/A
-206.44M
N/AN/AN/A
-83.30M
N/AN/AN/A
-116.09M
N/AN/AN/A
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.125, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.125